a 2018

CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo

PAVLASOVÁ, Gabriela, Marek BORSKÝ, Veronika SVOBODOVÁ, Jan OPPELT, Kateřina AMRUZ ČERNÁ et. al.

Basic information

Original name

CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo

Authors

PAVLASOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Veronika SVOBODOVÁ, Jan OPPELT (203 Czech Republic, belonging to the institution), Kateřina AMRUZ ČERNÁ (203 Czech Republic, belonging to the institution), Jitka NOVOTNÁ (203 Czech Republic, belonging to the institution), Kateřina MUSILOVÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Eva VOJÁČKOVÁ (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Marek MRÁZ (203 Czech Republic, guarantor, belonging to the institution)

Edition

AACR Annual Meeting Chicago Illinois USA, 2018

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10606 Microbiology

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14740/18:00104003

Organization unit

Central European Institute of Technology

Keywords in English

CD20; BCR; CLL

Tags

Změněno: 26/3/2019 15:25, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo, CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo.

Links

LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/0968/2017, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V (Acronym: VýDiTeHeMA V)
Investor: Masaryk University, Category A
MUNI/H/0865/2016, interní kód MU
Name: Coding and Non-coding RNA Networks that Regulate B Cell Receptor Signalling: Implications for Combinatorial Therapy
Investor: Masaryk University, Individual High risk/high gain projects
NV16-29622A, research and development project
Name: VLIV TERAPEUTICKÉ INHIBICE BCR SIGNALIZACE NA GENOVOU EXPRESI U B BUNĚČNÝCH MALIGNIT A JEJÍ PROGNOSTICKÝ A PREDIKTIVNÍ VÝZNAM
692298, interní kód MU
Name: MEDGENET - Medical genomics and epigenomics network (Acronym: MEDGENET)
Investor: European Union, Spreading excellence and widening participation